Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 Trial

PURPOSE: The EORTC-26101 study was a randomized phase II and III clinical trial of bevacizumab in combination with lomustine versus lomustine alone in progressive glioblastoma. Other than for progression-free survival (PFS), there was no benefit from addition of bevacizumab for overall survival (OS)...

Descripción completa

Detalles Bibliográficos
Autores principales: Kessler, Tobias, Schrimpf, Daniel, Doerner, Laura, Hai, Ling, Kaulen, Leon D., Ito, Jakob, van den Bent, Martin, Taphoorn, Martin, Brandes, Alba A., Idbaih, Ahmed, Dômont, Julien, Clement, Paul M., Campone, Mario, Bendszus, Martin, von Deimling, Andreas, Sahm, Felix, Platten, Michael, Wick, Wolfgang, Wick, Antje
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Precision Medicine and Imaging
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10543963/
https://www.ncbi.nlm.nih.gov/pubmed/37494539
http://dx.doi.org/10.1158/1078-0432.CCR-23-0926

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10543963/
https://www.ncbi.nlm.nih.gov/pubmed/37494539
http://dx.doi.org/10.1158/1078-0432.CCR-23-0926

Ejemplares similares